Siplizumab: A Deep Examination into MEDI-507 and 288392-69-8 Siplizumab, previously recognized as MEDI-507 and bearing the chemical designation 288392-69-8, represents a novel monoclonal designed to specifically target the CD25 molecule, a critical element of the IL-2 pathway. Its development focused on reducing T-cell proliferation by blocking CD